Shots:
- China’s NMPA has approved SonoVue for use in hysterosalpingo contrast sonography (HyCoSy) to detect tubal issues & uterine problems
- A meta-analysis of 24 studies in 1358 women with infertility & 2661 fallopian tubes showed superior diagnostic performance of HyCoSy with SonoVue, with pooled sensitivity of 93%, specificity of 90%, & accuracy of 96% vs laparoscopic chromotubation dye test
- SonoVue is a contrast agent that contains sulphur hexafluoride microbubbles to ensure earlier detection of fallopian tube blockage or uterine abnormalities, supporting non-invasive assessment of female infertility
Ref: Newswire | Image: Bracco Imaging | Press Release
Related News:- Bracco Imaging & Subtle Medical’s AiMIFY Receives the European CE Mark Approval for Enhanced Brain MRI
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
